高级检索
当前位置: 首页 > 详情页

Effect of Shenfu Injection on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China, [2]Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China, [3]Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China, [4]Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, United States
出处:
ISSN:

关键词: myocardial infarction primary percutaneous coronary intervention reperfusion injury Shenfu injection cardiac magnetic resonance imaging

摘要:
Background: Shenfu injection is a traditional Chinese medicine formulation that alleviates ischemia-reperfusion injury through multiple pharmacologic effects. However, no data are available regarding its efficacy in patients with myocardial infarction. We aimed to examine the effects of Shenfu injection on infarct size in patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).<br>Methods: From April 2016 to February 2018, 40 patients with first-time anterior STEMI undergoing primary PCI within 6 h of symptom onset were randomized 1:1 to intravenous Shenfu injection (80 ml Shenfu injection + 70 ml 5% glucose injection) or placebo (150 ml 5% glucose injection) before reperfusion. Treatment started before PCI and maintained for 5 days after PCI. The primary end point was infarct size assessed by CK-MB area under the curve (AUC) over 72 h and cardiac magnetic resonance (CMR) imaging 4 & PLUSMN; 1 days after PCI.<br>Results: Infarct size by area under the curve for CK-MB over 72 h did not differ between the Shenfu injection and placebo groups (5602.5 [3539.4-7526.4] vs. 6403.2 [2234.4-8340.6] ng & BULL;h/ml, P = 0.82). Among 32 patients who underwent CMR Imaging, a nominal reduction in infarct size was observed in the Shenfu injection group compared with the placebo group (23.9 [15.2-28.5] % vs. 27 [21.9-31.9] %, P = 0.42). After excluding patients with no or minimal infarct, there was a trend toward reduction in infarct size in the Shenfu injection group (24.1 [20.3-29.3] % vs. 29.1 [24.5-32] %, P = 0.18). Incidence of adverse events was similar between the groups.<br>Conclusions: This pilot study showed that the use of Shenfu injection was safe but did not reduce infarct size by CMR Imaging and CK-MB release kinetics in reperfused patients with STEMI. Larger studies (confining to patients with extensive infarct size) to evaluate the efficacy of Shenfu injection on reperfusion injury are warranted.Clinical Trail Registration: , identifier: NCT02709798.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 2 区 医学
小类 | 3 区 心脏和心血管系统
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 心脏和心血管系统
JCR分区:
出版当年[2019]版:
Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版:
Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2019版] 出版当年五年平均[2015-2019] 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China,
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Thorombolytic Therapy with Rescue Percutaneous Coronary Intervention Versus Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: A Multicenter Randomized Clinical Trial [2]Thorombolytic therapy with rescue percutaneous coronary intervention versus primary percutaneous coronary intervention in patients with acute myocardial infarction: a multicenter randomized clinical trial [3]Association of neutrophil/lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention [4]Elevated Admission Serum Creatinine Predicts Poor Myocardial Blood Flow and One-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients undergoing Primary Percutaneous Coronary Intervention [5]Protection by Atorvastatin Pretreatment in Patients Undergoing Primary Percutaneous Coronary Intervention Is Associated With the Lower Levels Of Oxygen Free Radicals [6]Increased serum adiponectin predicts improved coronary flow and clinical outcomes in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention [7]Clinical benefits of primary percutaneous coronary intervention for ST-elevation myocardial infarction patients with initial TIMI grade 3 flow in infarction-related artery [8]Elevated Admission Microalbuminuria Predicts Poor Myocardial Blood Flow and 6-Month Mortality in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention [9]Contemporary impact of circadian symptom-onset patterns of acute ST-Segment elevation myocardial infarction on long-term outcomes after primary percutaneous coronary intervention [10]Association between kaolin-induced maximum amplitude and slow-flow/ no-reflow in ST elevation myocardial infarction patients treated with primary percutaneous coronary intervention

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)